Most common grade ≥3 TEAEs occurring in ≥10% of patients by preferred term (safety population)
lymphoma, TEAE
LYMPHOMA, ADVERSE EVENT
TEAEs are defined as any adverse event that occurs after administration of the first dose of study treatment through 28 days after the last dose of study treatment, or until the start of subsequent antineoplastic therapy.All patients with lymphoma experienced at least one TEAE; 96% experienced a grade ≥3 TEAE, and 76% experienced a grade ≥3 TEAE considered by the investigator to be related to mivavotinib (